Teva launches generic Aggrenox capsules in US

Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or stroke due to a blood clot.

"The National Institutes of Health estimates 185,000 Americans are at risk of another stroke within 5 years of a previous stroke. Teva recognizes the devastating impact of a stroke and is pleased to launch generic aspirin and extended-release dipyridamole capsules as a treatment option for at-risk stroke patients," said Brendan O’Grady, President and CEO, North America Generic Medicines for Teva. "Being able to make affordable, high-quality generic medicines available to millions of patients every day is our commitment at Teva."

A stroke is caused when there is an interruption to the flow of oxygen rich blood to the brain. Without oxygen, brain cells can become damaged and die. Sudden bleeding in the brain can also cause a stroke if it damages brain cells. A stroke can result in brain damage, long-term disability, or even death.

On average, one American dies from stroke every four minutes. As the fifth leading cause of death in America, every year, more than 795,000 people have a stroke, and 25% have had a previous stroke. About 130,000 people will die as the result of a stroke each year.
Aggrenox (aspirin/extended-release dipyridamole) capsules had annual sales of approximately $457 million in the United States, according to IMS data as of April 2015.